Fukushima Ryan sold $1.1M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest disclosed fact is the $1.10M open-market sale executed across five trades on 2026-08-03 under a pre-arranged 10b5-1 plan, filed on 2026-08-05.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is routine 10b5-1 selling with no accompanying operational or financial update.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but provides no rationale for the sale; without follow-on buys or guidance changes, trading impact is likely limited.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05, covering sales executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction report for Tempus AI, Inc. (TEM) by CEO, Data Fukushima Ryan.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO Fukushima Ryan sold $1.10M of TEM shares via a 10b5-1 plan, with weighted-average prices $46.19 across five trades.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity management rather than bearish expectations, so any price reaction may be overstated.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale disclosure (TEM).

  • Fukushima Ryan

    CEO, Data who executed the indirect open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.